Day One Biopharmaceuticals (DAWN) Competitors $7.37 +0.11 (+1.52%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$7.38 +0.00 (+0.07%) As of 09/11/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. ARWR, VKTX, AMRX, XENE, KYMR, CRNX, RARE, MOR, BHC, and NAMSShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Arrowhead Pharmaceuticals (ARWR), Viking Therapeutics (VKTX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), MorphoSys (MOR), Bausch Health Cos (BHC), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Its Competitors Arrowhead Pharmaceuticals Viking Therapeutics Amneal Pharmaceuticals Xenon Pharmaceuticals Kymera Therapeutics Crinetics Pharmaceuticals Ultragenyx Pharmaceutical MorphoSys Bausch Health Cos NewAmsterdam Pharma Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Do insiders and institutionals believe in ARWR or DAWN? 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, ARWR or DAWN? Arrowhead Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Day One Biopharmaceuticals has a beta of -1.25, suggesting that its share price is 225% less volatile than the S&P 500. Do analysts prefer ARWR or DAWN? Arrowhead Pharmaceuticals currently has a consensus target price of $43.14, indicating a potential upside of 45.16%. Day One Biopharmaceuticals has a consensus target price of $25.29, indicating a potential upside of 243.09%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Day One Biopharmaceuticals is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is ARWR or DAWN more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -50.63%. Day One Biopharmaceuticals' return on equity of -19.01% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -40.91% -11.62% Day One Biopharmaceuticals -50.63%-19.01%-16.99% Does the media refer more to ARWR or DAWN? In the previous week, Arrowhead Pharmaceuticals had 17 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 24 mentions for Arrowhead Pharmaceuticals and 7 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 1.36 beat Arrowhead Pharmaceuticals' score of 0.57 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 7 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Day One Biopharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has higher earnings & valuation, ARWR or DAWN? Day One Biopharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$3.55M1,157.49-$599.49M-$1.28-23.22Day One Biopharmaceuticals$131.16M5.76-$95.50M-$0.95-7.76 SummaryDay One Biopharmaceuticals beats Arrowhead Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$743.66M$3.15B$5.78B$10.07BDividend YieldN/A2.32%5.69%4.62%P/E Ratio-7.7621.6075.2826.20Price / Sales5.76297.80474.0891.87Price / CashN/A45.3337.0859.91Price / Book1.489.7112.146.28Net Income-$95.50M-$53.33M$3.29B$270.85M7 Day Performance-2.38%1.04%1.57%3.58%1 Month Performance20.03%9.93%7.85%6.67%1 Year Performance-46.09%13.80%62.01%27.73% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals2.9744 of 5 stars$7.37+1.5%$25.29+243.1%-47.7%$743.66M$131.16M-7.7660Positive NewsARWRArrowhead Pharmaceuticals4.1782 of 5 stars$22.03-1.4%$43.14+95.8%+41.9%$3.05B$3.55M-17.21400VKTXViking Therapeutics4.3271 of 5 stars$27.05-1.9%$86.92+221.3%-57.7%$3.04BN/A-17.6820Positive NewsAMRXAmneal Pharmaceuticals2.6782 of 5 stars$9.56+0.1%$11.60+21.3%+20.7%$3.00B$2.79B956.968,100Positive NewsXENEXenon Pharmaceuticals2.5367 of 5 stars$38.71+0.3%$53.20+37.4%-3.7%$2.98B$9.43M-10.90210Positive NewsKYMRKymera Therapeutics2.6858 of 5 stars$41.20-1.3%$58.76+42.6%+3.2%$2.95B$47.07M-11.87170Positive NewsCRNXCrinetics Pharmaceuticals3.7332 of 5 stars$30.99+1.1%$68.86+122.2%-33.5%$2.92B$1.04M-7.54210Positive NewsRAREUltragenyx Pharmaceutical4.4264 of 5 stars$29.96-1.1%$81.50+172.0%-44.6%$2.89B$560.23M-5.421,294Positive NewsAnalyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730BHCBausch Health Cos4.755 of 5 stars$7.41+3.6%$9.00+21.5%+13.7%$2.75B$9.63B28.5020,700Positive NewsNAMSNewAmsterdam Pharma3.3901 of 5 stars$24.05+0.4%$41.55+72.7%+64.6%$2.71B$45.56M-14.854News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Competitors Viking Therapeutics Competitors Amneal Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Kymera Therapeutics Competitors Crinetics Pharmaceuticals Competitors Ultragenyx Pharmaceutical Competitors MorphoSys Competitors Bausch Health Cos Competitors NewAmsterdam Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
